SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Axogen, Inc. – ‘10-K’ for 12/31/20 – ‘EX-32.1’

On:  Monday, 3/1/21, at 6:10am ET   ·   For:  12/31/20   ·   Accession #:  805928-21-44   ·   File #:  1-36046

Previous ‘10-K’:  ‘10-K/A’ on 6/12/20 for 12/31/19   ·   Next:  ‘10-K’ on 2/25/22 for 12/31/21   ·   Latest:  ‘10-K’ on 3/5/24 for 12/31/23   ·   43 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/01/21  Axogen, Inc.                      10-K       12/31/20   94:10M

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.39M 
 2: EX-21.1     Subsidiaries List                                   HTML     24K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML     24K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     29K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     26K 
13: R1          Cover                                               HTML     89K 
14: R2          Consolidated Balance Sheets                         HTML    103K 
15: R3          Consolidated Balance Sheets (Parenthetical)         HTML     36K 
16: R4          Consolidated Statements of Operations               HTML     80K 
17: R5          Consolidated Statements of Changes in               HTML     80K 
                Shareholders' Equity                                             
18: R6          Consolidated Statements of Cash Flows               HTML    149K 
19: R7          Basis of Presentation                               HTML     27K 
20: R8          Organization and Business                           HTML     31K 
21: R9          Summary of Significant Accounting Policies          HTML     76K 
22: R10         Inventory                                           HTML     34K 
23: R11         Fair Value Measurement                              HTML     88K 
24: R12         Prepaid Expense and Other                           HTML     36K 
25: R13         Property and Equipment                              HTML     39K 
26: R14         Intangible Assets                                   HTML     59K 
27: R15         Accounts Payable and Accrued Expenses               HTML     33K 
28: R16         Long-Term Debt                                      HTML     45K 
29: R17         Public Offering of Common Stock                     HTML     28K 
30: R18         Equity Compensation Plans                           HTML     88K 
31: R19         Income Taxes                                        HTML     66K 
32: R20         Employee Benefit Plan                               HTML     31K 
33: R21         Commitments and Contingencies                       HTML     97K 
34: R22         Quarterly Results of Operations (Unaudited)         HTML     52K 
35: R23         Subsequent Events                                   HTML     27K 
36: R24         Schedule II - Valuation and Qualifying Accounts     HTML     46K 
37: R25         Summary of Significant Accounting Policies          HTML     98K 
                (Policies)                                                       
38: R26         Summary of Significant Accounting Policies          HTML     45K 
                (Tables)                                                         
39: R27         Inventory (Tables)                                  HTML     34K 
40: R28         Fair Value Measurement (Tables)                     HTML     87K 
41: R29         Prepaid Expense and Other (Tables)                  HTML     36K 
42: R30         Property and Equipment (Tables)                     HTML     37K 
43: R31         Intangible Assets (Tables)                          HTML     80K 
44: R32         Accounts Payable and Accrued Expenses (Tables)      HTML     33K 
45: R33         Long-Term Debt (Tables)                             HTML     35K 
46: R34         Equity Compensation Plans (Tables)                  HTML     84K 
47: R35         Income Taxes (Tables)                               HTML     60K 
48: R36         Commitments and Contingencies (Tables)              HTML     87K 
49: R37         Quarterly Results of Operations (Unaudited)         HTML     52K 
                (Tables)                                                         
50: R38         Summary of Significant Accounting Policies -        HTML     55K 
                Narrative (Details)                                              
51: R39         Summary of Significant Accounting Policies -        HTML     34K 
                Reconciliation of Cash (Details)                                 
52: R40         Summary of Significant Accounting Policies -        HTML     39K 
                Contract Balances (Details)                                      
53: R41         Inventory (Details)                                 HTML     37K 
54: R42         Fair Value Measurement - Schedule of Assets and     HTML     88K 
                Liabilities Measured at Fair Value on a Recurring                
                Basis (Details)                                                  
55: R43         Fair Value Measurement - Narrative (Details)        HTML     28K 
56: R44         Fair Value Measurement - Significant Inputs         HTML     42K 
                Included in the Valuation of the Debt Derivative                 
                Liability (Details)                                              
57: R45         Fair Value Measurement - Fair Value of Instruments  HTML     43K 
                Classified as Level 3 (Details)                                  
58: R46         Prepaid Expenses and Other - Schedule of Prepaid    HTML     45K 
                Expense and Other (Details)                                      
59: R47         Prepaid Expense and Other - Narrative (Details)     HTML     28K 
60: R48         Property and Equipment (Details)                    HTML     44K 
61: R49         Property and Equipment - Narrative (Details)        HTML     40K 
62: R50         Intangible Assets - Components of Intangible        HTML     47K 
                Assets (Details)                                                 
63: R51         Intangible Assets - Narrative (Details)             HTML     62K 
64: R52         Intangible Assets - Future Amortization of Patents  HTML     43K 
                and License Agreements (Details)                                 
65: R53         Accounts Payable and Accrued Expenses (Details)     HTML     35K 
66: R54         Long-Term Debt - Schedule of Carrying Values of     HTML     33K 
                Outstanding Debt (Details)                                       
67: R55         Long-Term Debt - Narrative (Details)                HTML    113K 
68: R56         Public Offering of Common Stock (Details)           HTML     29K 
69: R57         Equity Compensation Plans - Overview of Equity      HTML     50K 
                Incentive Plans Narrative (Details)                              
70: R58         Equity Compensation Plans - Grant Date Fair Value   HTML     34K 
                (Details)                                                        
71: R59         Equity Compensation Plans - Stock Options           HTML     57K 
                Narrative (Details)                                              
72: R60         Equity Compensation Plans - Summary of Stock        HTML     76K 
                Option Activity (Details)                                        
73: R61         Equity Compensation Plans - Summary of              HTML     35K 
                Weighted-Average Assumptions Used (Details)                      
74: R62         Equity Compensation Plans - Restricted and          HTML     97K 
                Performance Stock Units Narrative (Details)                      
75: R63         Equity Compensation Plans - Summary of Restricted   HTML     57K 
                and Performance Stock Units (Details)                            
76: R64         Equity Compensation Plans - Employee Stock          HTML     36K 
                Purchase Plan (Details)                                          
77: R65         Income Taxes - Temporary Differences (Details)      HTML     59K 
78: R66         Income Taxes - Effective Income Tax Rate            HTML     37K 
                Reconciliation (Details)                                         
79: R67         Income Taxes - Narrative (Details)                  HTML     44K 
80: R68         Employee Benefit Plan (Details)                     HTML     39K 
81: R69         Commitments and Contingencies - Leases Narrative    HTML     40K 
                (Details)                                                        
82: R70         Commitments and Contingencies - Lease Expense       HTML     39K 
                (Details)                                                        
83: R71         Commitments and Contingencies - Supplemental        HTML     48K 
                Balance Sheet Information Related to Leases                      
                (Details)                                                        
84: R72         Commitments and Contingencies - Other Information   HTML     39K 
                Related to Leases (Details)                                      
85: R73         Commitments and Contingencies - Maturities of       HTML     69K 
                Lease Payments (Details)                                         
86: R74         Commitments and Contingencies - Service Agreements  HTML     43K 
                Narrative (Details)                                              
87: R75         Commitments and Contingencies - Concentrations      HTML     52K 
                Narrative (Details)                                              
88: R76         Commitments and Contingencies - Litigation          HTML     33K 
                Narrative (Details)                                              
89: R77         Quarterly Results of Operations (Unaudited)         HTML     48K 
                (Details)                                                        
90: R78         Schedule II - Valuation and Qualifying Accounts     HTML     39K 
                (Details)                                                        
92: XML         IDEA XML File -- Filing Summary                      XML    171K 
12: XML         XBRL Instance -- axgn-20201231_htm                   XML   2.13M 
91: EXCEL       IDEA Workbook of Financial Reports                  XLSX    121K 
 8: EX-101.CAL  XBRL Calculations -- axgn-20201231_cal               XML    283K 
 9: EX-101.DEF  XBRL Definitions -- axgn-20201231_def                XML    707K 
10: EX-101.LAB  XBRL Labels -- axgn-20201231_lab                     XML   1.96M 
11: EX-101.PRE  XBRL Presentations -- axgn-20201231_pre              XML   1.15M 
 7: EX-101.SCH  XBRL Schema -- axgn-20201231                         XSD    202K 
93: JSON        XBRL Instance as JSON Data -- MetaLinks              462±   683K 
94: ZIP         XBRL Zipped Folder -- 0000805928-21-000044-xbrl      Zip    572K

‘EX-32.1’   —   Certification — §906 – SOA’02

This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]

 <!   C:   C: 
  Document  
EXHIBIT 32.1
CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES -OXLEY ACT OF 2002
In connection with the Annual Report of Axogen, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission (the “Report”), I, Karen Zaderej, Chief Executive Officer and Peter Mariani, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Karen Zaderej
Karen Zaderej
Chief Executive Officer
March 1, 2021
/s/ Peter Mariani
Peter Mariani
Chief Financial Officer
March 1, 2021


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/1/214
For Period end:12/31/204,  DEF 14A
 List all Filings 

3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/25/22  Axogen, Inc.                      POSASR      2/25/22    4:169K                                   Broadridge Fin’l So… Inc
 5/11/21  Axogen, Inc.                      S-8         5/11/21    3:61K                                    Donnelley … Solutions/FA
 5/06/21  Axogen, Inc.                      S-3ASR      5/06/21    3:178K                                   Donnelley … Solutions/FA

40 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/06/21  Axogen, Inc.                      8-K:5,9     1/04/21   11:1.3M                                   Toppan Merrill Bridge/FA
12/04/20  Axogen, Inc.                      8-K:1,9    11/30/20   11:175K                                   Toppan Merrill Bridge/FA
10/30/20  Axogen, Inc.                      10-Q        9/30/20   72:8.1M                                   Toppan Merrill Bridge/FA
10/29/20  Axogen, Inc.                      8-K:2,5,9  10/29/20   18:5.4M                                   Toppan Merrill Bridge/FA
 7/01/20  Axogen, Inc.                      8-K:1,2,3,9 6/30/20   15:1.7M                                   Toppan Merrill Bridge/FA
 6/01/20  Axogen, Inc.                      8-K:5,8,9   5/28/20   13:551K                                   Toppan Merrill Bridge/FA
 2/24/20  Axogen, Inc.                      10-K       12/31/19   84:9.7M                                   Toppan Merrill Bridge/FA
11/06/19  Axogen, Inc.                      10-Q        9/30/19   69:6.3M                                   Toppan Merrill Bridge/FA
 7/12/19  Axogen, Inc.                      8-K:1,9     7/09/19    2:10M                                    Toppan Merrill Bridge/FA
 5/08/19  Axogen, Inc.                      10-Q        3/31/19   63:4.9M                                   Toppan Merrill Bridge/FA
 5/02/19  Axogen, Inc.                      8-K:5,9     4/26/19    3:287K                                   Toppan Merrill Bridge/FA
 2/26/19  Axogen, Inc.                      10-K       12/31/18   83:8.7M                                   Toppan Merrill Bridge/FA
 1/22/19  AxoGen, Inc.                      8-K:5,9     1/21/19    4:434K                                   Toppan Merrill Bridge/FA
 1/18/19  AxoGen, Inc.                      8-K:5,9     1/18/19    2:161K                                   Toppan Merrill Bridge/FA
 1/16/19  AxoGen, Inc.                      8-K:5,9     1/15/19    2:148K                                   Toppan Merrill Bridge/FA
11/26/18  AxoGen, Inc.                      8-K:1,9    11/19/18    5:983K                                   Toppan Merrill Bridge/FA
10/29/18  AxoGen, Inc.                      8-K:1,2,5,910/26/18    8:1.7M                                   Toppan Merrill Bridge/FA
 9/21/18  AxoGen, Inc.                      8-K:1,2,9   9/20/18    3:896K                                   Toppan Merrill Bridge/FA
 7/12/18  AxoGen, Inc.                      8-K:1,5,9   7/09/18    3:325K                                   Toppan Merrill Bridge/FA
 4/13/18  AxoGen, Inc.                      8-K:1,9     4/10/18    2:91K                                    Toppan Merrill Bridge/FA
 2/28/18  AxoGen, Inc.                      10-K       12/31/17   80:8.1M                                   Toppan Merrill Bridge/FA
 4/07/17  AxoGen, Inc.                      DEF 14A     5/24/17    1:1.5M                                   Toppan Merrill Bridge/FA
 3/01/17  AxoGen, Inc.                      10-K       12/31/16   82:9.8M                                   Toppan Merrill Bridge/FA
 1/26/17  AxoGen, Inc.                      8-K:1,9     1/23/17    2:456K                                   Toppan Merrill Bridge/FA
10/31/16  AxoGen, Inc.                      8-K:1,2,8,910/25/16    3:169K                                   Toppan Merrill Bridge/FA
 7/11/16  AxoGen, Inc.                      8-K:1,9     7/05/16    2:492K                                   Toppan Merrill Bridge/FA
 5/31/16  AxoGen, Inc.                      8-K:5,9     5/26/16    2:102K                                   Toppan Merrill Bridge/FA
 4/08/16  AxoGen, Inc.                      DEF 14A     5/26/16    1:1.4M                                   Toppan Merrill Bridge/FA
 3/18/16  AxoGen, Inc.                      8-K:1,9     3/16/16    2:190K                                   Toppan Merrill Bridge/FA
 3/14/16  AxoGen, Inc.                      8-K:5,9     3/14/16    2:325K                                   Toppan Merrill Bridge/FA
11/05/15  AxoGen, Inc.                      10-Q        9/30/15   54:4.7M                                   Toppan Merrill Bridge/FA
 4/22/15  AxoGen, Inc.                      8-K:1,9     4/16/15    3:607K                                   Toppan Merrill/FA
11/13/14  AxoGen, Inc.                      10-Q        9/30/14   47:2.6M                                   Toppan Merrill/FA
 8/04/14  AxoGen, Inc.                      10-Q        6/30/14   46:2.5M                                   Toppan Merrill/FA
 3/06/14  AxoGen, Inc.                      10-K       12/31/13   68:12M                                    Toppan Merrill/FA
 3/12/13  AxoGen, Inc.                      10-K       12/31/12   74:6.3M                                   Donnelley … Solutions/FA
 3/15/12  AxoGen, Inc.                      10-K       12/31/11   41:3.3M                                   Donnelley … Solutions/FA
11/14/11  AxoGen, Inc.                      10-Q        9/30/11   30:2M                                     Donnelley … Solutions/FA
10/06/11  AxoGen, Inc.                      8-K:1,2,3,5 9/30/11   14:1.7M                                   Donnelley … Solutions/FA
 9/26/07  Axogen, Inc.                      8-K:5,8,9   9/20/07    3:29K                                    Bowne Boc/FA
↑Top
Filing Submission 0000805928-21-000044   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., May 15, 6:43:33.4pm ET